BioNTech SE (F:22UAy) (NASDAQ:BNTX) has been downgraded to “market perform” from “outperform” by Leerink Partners after a ...

Bristol-Myers Squibb (NYSE:BMY) has outlined a broad pipeline refresh that includes multiple recent product launches and the announcement of a new R&D facility. The company has agreed to acquire ...

After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.

The downgrade follows a 24% rise in BioNTech’s shares to $113 from December lows of $92, a move that outpaced the 4% gain in the S&P Biotechnology Select Industry Index over the same period. Leerink ...

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...

U.S.-based pharmaceutical giant German biotech company BioNTech were already collaborating to come up with a flu vaccine ...

BioNTech has turned to dealmaking yet again to diversify its cancer drug pipeline, paying $170 million to begin an alliance with Duality Biologics. The deal includes a clinical-stage drug candidate ...

BERLIN (Reuters) -BioNTech will invest 40 million euros ($43 million) in a new facility in Germany that will allow it to produce an important building block in mRNA-based drugs, the German ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

BioNTech SE (NASDAQ:BNTX) on Thursday agreed to acquire CureVac N.V. (NASDAQ:CVAC) in an all-stock transaction. According to the agreement, shareholders can exchange CureVac shares for around $5.46 in ...

Germany's BioNTech is launching a U.K. trial of personalized mRNA therapies, including cancer vaccines, from September. It aims to deliver 10,000 therapies to patients before 2030. Campaigners called ...